154 related articles for article (PubMed ID: 19006678)
1. A cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight.
Ucar SK; Coker M; Argin M; Akman S; Kara S; Simsek DG; Darcan S
Mol Genet Metab; 2009 Jan; 96(1):50-1. PubMed ID: 19006678
[TBL] [Abstract][Full Text] [Related]
2. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy.
Langeveld M; de Fost M; Aerts JM; Sauerwein HP; Hollak CE
Blood Cells Mol Dis; 2008; 40(3):428-32. PubMed ID: 17950007
[TBL] [Abstract][Full Text] [Related]
3. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
Lebel E; Elstein D; Peleg A; Reinus C; Zimran A; Amir G
Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?
Brunel-Guitton C; Rivard GE; Galipeau J; Alos N; Miron MC; Therrien R; Mitchell G; Lapierre G; Lambert M
Mol Genet Metab; 2009 Feb; 96(2):73-6. PubMed ID: 19083253
[TBL] [Abstract][Full Text] [Related]
5. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
[TBL] [Abstract][Full Text] [Related]
6. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
7. [French results of enzyme replacement therapy in Gaucher's disease].
Schaison G; Caubel I; Belmatoug N; Billette de Villemeur T; Saudubray JM
Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
[TBL] [Abstract][Full Text] [Related]
8. Prospects for enzyme replacement therapy in Gaucher disease.
Brady RO; Barranger JA; Furbish FS; Stowens DW; Ginns EI
Prog Clin Biol Res; 1982; 95():669-80. PubMed ID: 7122643
[No Abstract] [Full Text] [Related]
9. Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT).
Giona F; Palumbo G; Amendola A; Santoro C; Mazzuconi MG
J Thromb Haemost; 2006 Aug; 4(8):1831-3. PubMed ID: 16879228
[No Abstract] [Full Text] [Related]
10. Outcome of enzyme replacement therapy in Turkish patients with Gaucher disease: does late intervention affect the response?
Arikan-Ayyildiz Z; Yüce A; Emre S; Baysoy G; Saltik-Temizel IN; Gürakan F
Turk J Pediatr; 2011; 53(5):499-507. PubMed ID: 22272449
[TBL] [Abstract][Full Text] [Related]
11. [Gaucher's disease and enzyme replacement therapy].
Cornu F
Ann Pharm Fr; 1998; 56(3):102-7. PubMed ID: 9770016
[TBL] [Abstract][Full Text] [Related]
12. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
Sechi A; Deroma L; Dardis A; Ciana G; Bertin N; Concolino D; Linari S; Perria C; Bembi B
Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
[TBL] [Abstract][Full Text] [Related]
13. [Gaucher disease: MR evaluation of bone marrow features during treatment with enzyme replacement].
Poll LW; vom Dahl S; Koch JA; Börner D; Willers R; Cohnen M; Jung G; Scherer A; Niederau C; Häussinger D; Mödder U
Rofo; 2001 Oct; 173(10):931-7. PubMed ID: 11588682
[TBL] [Abstract][Full Text] [Related]
14. Gaucher disease: a century of delineation and research. Enzyme replacement therapy: model and clinical studies.
Beutler E; Dale GL
Prog Clin Biol Res; 1982; 95():703-16. PubMed ID: 7122644
[TBL] [Abstract][Full Text] [Related]
15. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
Kauli R; Zaizov R; Lazar L; Pertzelan A; Laron Z; Galatzer A; Phillip M; Yaniv Y; Cohen IJ
Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
[TBL] [Abstract][Full Text] [Related]
16. Liposomes in Gaucher type I disease: use in enzyme therapy and the creation of an animal model.
Gregoriadis G; Weereratne H; Blair H; Bull GM
Prog Clin Biol Res; 1982; 95():681-701. PubMed ID: 6812092
[No Abstract] [Full Text] [Related]
17. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
Elstein D; Cohn GM; Wang N; Djordjevic M; Brutaru C; Zimran A
Blood Cells Mol Dis; 2011 Jan; 46(1):119-23. PubMed ID: 20727796
[TBL] [Abstract][Full Text] [Related]
18. Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy.
Kacher Y; Brumshtein B; Boldin-Adamsky S; Toker L; Shainskaya A; Silman I; Sussman JL; Futerman AH
Biol Chem; 2008 Nov; 389(11):1361-9. PubMed ID: 18783340
[TBL] [Abstract][Full Text] [Related]
19. Enzyme replacement therapy for Gaucher Disease: the only experience in Malaysia.
Chan LL; Lin HP
Med J Malaysia; 2002 Sep; 57(3):348-52. PubMed ID: 12440275
[TBL] [Abstract][Full Text] [Related]
20. Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy.
Santoro D; Rosenbloom BE; Cohen AH
Am J Kidney Dis; 2002 Jul; 40(1):E4. PubMed ID: 12087590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
